RADRadiopharm Theranostics
About Radiopharm Theranostics
Radiopharm Theranostics (ASX:RAD) is a radiopharmaceutical company that develops and commercialises innovative diagnostic and therapeutic products for the treatment of cancer and other diseases. Radiopharm Theranostics’ operations are focused on the development of new radiopharmaceuticals, as well as the commercialisation of its existing products in Australia and other international markets. The company aims to develop and commercialise innovative radiopharmaceutical products for the treatment of cancer and other diseases.
What is RAD known for?
Snapshot
Public AU
Ownership
2021
Year founded
19
Employees
Sydney, Australia
Head office
1 of 824
AU Rank
Unknown
Sector
N/A
Sector rank
Loading Map...
Operations
All Locations
Australia
Products and/or services of Radiopharm Theranostics
- Nano-mAbs: an esteemed radiopharmaceutical and nuclear medicine specialist formerly associated with the University of Oxford, is a pioneering radiopharmaceutical platform.
- Pivalate: derived from a short-chain carbohydrate. It exploits early stages of fatty acid oxidation and exhibits remarkable stability.
- AVß6: a potent ligand targeting the cell surface protein avß6-integrin. It selectively accumulates in areas with heightened avß6-integrin levels.
- DUNP19: designed to simultaneously address tumours and their surrounding tumour micro-environment cells, including stromal and immune cells.
- PTPµ (PTPmu): a peptide molecule biomarker designed for the precise detection, imaging, and treatment of tumours.
Radiopharm Theranostics executive team
- Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICDFounder & Executive Chairman
- Mr. Riccardo CanevariMD, CEO & Director
- Mr. Phillip HainsCFO & Joint Company Secretary
- Dr. Dimitris Voliotis M.D.Chief Medical Officer
- Mr. Hitesh GoelHead of Project Management
- Mr. Nathan Jong C.A.Joint Company Secretary